Drew Tietz

Drew Tietz has a diverse work experience in the field of scientific research. Drew is currently working at Sigilon Therapeutics, Inc. as a Principal Scientist since July 2021. Prior to this role, they served as a Senior Scientist at the same company from November 2018 to July 2021. Before joining Sigilon Therapeutics, Inc., Drew worked as a Research and Development Scientist at Thermo Fisher Scientific from June 2017 to November 2018. Drew also gained experience as a Scientist II at Sanofi Genzyme from October 2015 to June 2017. Drew's earlier work includes being a Research Fellow at Brandeis University from 2009 to December 2015, and a Researcher at Kutztown University in 2008. Drew also worked as a Researcher at Lehigh University from May 2008 to August 2008.

Drew Tietz earned a Bachelor of Science degree in Chemistry, with a minor in Biochemistry, from Kutztown University in 2008. Drew later pursued a PhD in Physical Chemistry at Brandeis University, completing their studies in 2015. Prior to their college education, Drew attended Vernon High School, although no degree or field of study is specified.